Spero Therapeutics (NASDAQ:SPRO) Receives Buy Rating from Stifel Nicolaus

Stifel Nicolaus reaffirmed their buy rating on shares of Spero Therapeutics (NASDAQ:SPRO) in a report issued on Tuesday, The Fly reports. Stifel Nicolaus currently has a $25.00 price objective on the stock, up from their previous price objective of $21.00.

A number of other equities analysts have also recently commented on the company. Zacks Investment Research cut Spero Therapeutics from a buy rating to a hold rating in a report on Friday, August 28th. Oppenheimer restated a buy rating on shares of Spero Therapeutics in a report on Monday, August 31st. Finally, HC Wainwright restated a buy rating and set a $28.00 price objective on shares of Spero Therapeutics in a report on Tuesday, June 2nd. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of Buy and an average price target of $21.75.

Spero Therapeutics stock opened at $9.91 on Tuesday. Spero Therapeutics has a 52 week low of $5.25 and a 52 week high of $14.48. The company has a debt-to-equity ratio of 0.06, a quick ratio of 4.49 and a current ratio of 4.49. The stock has a market capitalization of $209.60 million, a P/E ratio of -2.28 and a beta of 1.69. The stock has a 50-day simple moving average of $11.84 and a 200 day simple moving average of $10.95.

Spero Therapeutics (NASDAQ:SPRO) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.85) EPS for the quarter, topping analysts’ consensus estimates of ($1.17) by $0.32. Spero Therapeutics had a negative return on equity of 103.39% and a negative net margin of 715.20%. The business had revenue of $1.73 million during the quarter, compared to analysts’ expectations of $2.95 million. Research analysts forecast that Spero Therapeutics will post -3.68 earnings per share for the current year.

In related news, CEO Ankit Mahadevia sold 2,293 shares of the business’s stock in a transaction that occurred on Thursday, July 9th. The stock was sold at an average price of $14.31, for a total value of $32,812.83. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last quarter, insiders sold 3,821 shares of company stock valued at $54,587. 18.34% of the stock is currently owned by corporate insiders.

Several hedge funds have recently modified their holdings of SPRO. Marshall Wace LLP bought a new stake in shares of Spero Therapeutics in the first quarter valued at approximately $39,000. Janney Montgomery Scott LLC boosted its stake in shares of Spero Therapeutics by 7.4% in the first quarter. Janney Montgomery Scott LLC now owns 14,500 shares of the company’s stock valued at $117,000 after buying an additional 1,000 shares during the period. BlackRock Inc. boosted its stake in shares of Spero Therapeutics by 16.7% in the first quarter. BlackRock Inc. now owns 881,231 shares of the company’s stock valued at $7,120,000 after buying an additional 125,966 shares during the period. Los Angeles Capital Management & Equity Research Inc. bought a new stake in shares of Spero Therapeutics in the first quarter valued at approximately $123,000. Finally, New York State Common Retirement Fund boosted its stake in shares of Spero Therapeutics by 11.4% in the first quarter. New York State Common Retirement Fund now owns 18,429 shares of the company’s stock valued at $149,000 after buying an additional 1,879 shares during the period. Institutional investors and hedge funds own 50.40% of the company’s stock.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. Its product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative infections in the hospital; and SPR720, an oral antibiotic for the treatment of pulmonary non-tuberculous mycobacterial disease.

See Also: Municipal Bonds

The Fly

Analyst Recommendations for Spero Therapeutics (NASDAQ:SPRO)

Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit